Current Stem Cell Research & Therapy

ISSN: 1574-888X

Current Stem Cell Research & Therapy
Volume 2, Number 1, January 2007

Contents


The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma: Is there Still a Role for PBSC Transplantation? Pp. 1-11
Alessandro Corso and Marzia Varettoni
[Abstract] [Full Text Article]


Neural Stem Cells as Biological Minipumps: A Faster Route to Cell Therapy for the CNS? Pp. 13-22
H. Isaac Chen, Asha Bakshi, Nicolas C. Royo, Suresh N. Magge and Deborah J. Watson
[Abstract] [Full Text Article]


The Role of Stroma in Hematopoiesis and Dendritic Cell Development Pp. 23-29
Geneviève Despars, Jonathan Tan, Pravin Periasamy and Helen C. O’Neill
[Abstract] [Full Text Article]


Telomerase Activation in Liver Regeneration and Hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde? Pp. 31-38
Henning Wege and Tim H. Brümmendorf
[Abstract] [Full Text Article]


Function and Malfunction of Hematopoietic Stem Cells in Primary Bone Marrow Failure Syndromes Pp. 39-52
Antonio M. Risitano, Jaroslaw P. Maciejewski, Carmine Selleri and Bruno Rotoli
[Abstract] [Full Text Article]


Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges Pp. 53-63
Marc Bierings, James B. Nachman and C. Michel Zwaan
[Abstract] [Full Text Article]


High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review Pp. 65-82
Giuseppe Luigi Banna, Matteo Simonelli and Armando Santoro
[Abstract] [Full Text Article]


Regenerative Medicine and Liver Injury: What Role for Bone Marrow Derived Stem Cells? Pp. 83-88
Stefania Lorenzini and Pietro Andreone
[Abstract] [Full Text Article]


Stem Cell Migration: A Quintessential Stepping Stone to Successful Therapy Pp. 89-103
Corinna Weidt, Bernd Niggemann, Benjamin Kasenda, Theodore L. Drell, Kurt S. Zänker and Thomas Dittmar
[Abstract] [Full Text Article]


Hematopoietic Stem Cell Transplantation from Alternative Donors for High-Risk Acute Leukemia: The Haploidentical Option Pp. 105-112
Franco Aversa, Antonio Tabilio, Andrea Velardi, Adelmo Terenzi, Franca Falzetti, Alessandra Carotti, Teresa Aloisi, Maria Liga, Mauro Di Ianni, Tiziana Zei, Antonella Santucci and Massimo F. Martelli
[Abstract] [Full Text Article]




Abstracts

[Back to top]
The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma: Is there Still a Role for PBSC Transplantation?
Alessandro Corso and Marzia Varettoni

[Full Text Article]

High-dose therapy with the rescue of autologous stem cells represents today the standard approach for multiple myeloma patients aged <65 years. Several studies, in fact, have demonstrated the superiority of high-dose therapy with respect to conventional chemotherapy in younger patients. Peripheral blood stem cells (PBSCs) provide a rapid and effective hematopoietic recovery after the administration of supra maximal chemotherapy and mainly for this reason have become the preferred source of stem cells for autologous transplantation. Recently, however, a number of new drugs have appeared in the armamentarium of the hematologist. Among these, thalidomide has been the first antiangiogenetic drug effectively adopted firstly in refractory-relapsed patients and now also as first line treatment with better results respect to VAD or VAD-like regimens. Inhibitors of proteasome, such as bortezomib, and other immunomodulatory agents, such as lenalidomide, have been also studied more recently in myeloma patients. In particular, bortezomib has shown to be very effective as single agent or in combination with high-dose dexamethasone.

In this review, we try to define the potential role of these new drugs, how and when they can be included in the therapeutic program designed for younger and older patients, and mostly if and how these new agents could jeopardize the central role of autologous stem cell transplantation in the treatment of multiple myeloma.


[Back to top]
Neural Stem Cells as Biological Minipumps: A Faster Route to Cell Therapy for the CNS?
H. Isaac Chen, Asha Bakshi, Nicolas C. Royo, Suresh N. Magge and Deborah J. Watson

[Full Text Article]

One strategy for the use of neural stem cells (NSCs) in treating neurological disorders is as transplantable “biological minipumps”, in which genetically engineered neural stem cells serve as sources of secreted therapeutic (neuroprotective or tumoricidal) agents. Neural stem cells are highly mobile within the brain and demonstrate a tropism for various types of central nervous system (CNS) pathology, making them promising candidates for targeted gene delivery vehicles. Although neural stem cells have also been proposed as a potential source of replacement neurons and astrocytes to repopulate injured or degenerating neural circuits, the challenges involved in rebuilding damaged brain architecture are substantial and remain an active area of investigation. In contrast, the use of NSCs as biological minpumps does not rely on neuronal differentiation, axonal targeting, or synaptogenesis. This strategy may be a faster route to cell-based therapy of the CNS and is poised to move into human clinical trials. This review considers two types of neurologic disease that may be suitable targets for this alternative approach to NSC therapy: glial brain tumors and traumatic brain injury. We examine some of the key scientific and technical issues that must be addressed for the successful use of NSCs as minipumps.


[Back to top]
The Role of Stroma in Hematopoiesis and Dendritic Cell Development
Geneviève Despars, Jonathan Tan, Pravin Periasamy and Helen C. O’Neill

[Full Text Article]

Development of the immune system is depicted as a hierarchical process of differentiation from hematopoietic stem cells (HSC) to lineage-committed precursors, which further develop into mature immune cells. In the case of dendritic cell (DC) development, this linear precursor-progeny approach has led to a confused picture of relationships between various subsets of DC identifiable in vivo. A possible reconciliation of the diversity of DC precursors and DC subsets in vivo encompasses the role of the microenvironment in DC hematopoiesis. We propose here that various niches for DC hematopoiesis within lymphoid organs could account for the diversity of DC in vivo. A tridimensional space consisting of stromal cells which produce a range of membrane-bound and secreted molecules providing signals to DC progenitors would define these niches.


[Back to top]
Telomerase Activation in Liver Regeneration and Hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde?
Henning Wege and Tim H. Brümmendorf

[Full Text Article]

The liver has a remarkable capability to restore its functional capacity following liver injury. According to the current paradigm, differentiated and usually quiescent hepatocytes are the primary cell type responsible for liver repair. As reserve compartment, bipotent hepatic progenitor cells are activated, especially if extensive loss or damage of hepatocytes with impaired replication occurs, e.g. in cirrhotic liver tissue. Recently, animal studies have suggested that liver regeneration following partial hepatectomy is associated with telomerase activation. Telomerase, a ribonucleoprotein with reverse transcriptase activity, plays a pivotal role in maintaining telomere length and chromosomal stability in proliferating cells. In cells lacking telomerase activity, replication-associated telomere shortening limits the replicative lifespan. Therefore, in the context of liver regeneration, telomerase activation might be a cellular mechanism to confer an extended lifespan to replicating hepatocytes and hepatic progenitor cells. On the other hand, high levels of telomerase activity are a hallmark of cancer, including hepatocellular carcinoma. Moreover, recent data indicate that telomerase activation may be an early event in hepatocarcinogenesis. At present, it is unclear, whether telomerase activation preserves the non-malignant phenotype and replicative longevity of liver cells or constitutes an early alteration obligatory for an unlimited proliferation and malignant transformation.


[Back to top]
Function and Malfunction of Hematopoietic Stem Cells in Primary Bone Marrow Failure Syndromes
Antonio M. Risitano, Jaroslaw P. Maciejewski, Carmine Selleri and Bruno Rotoli

[Full Text Article]

Hematopoietic stem cells (HSCs) are responsible for the production of mature blood cells in bone marrow; peripheral pancytopenia is a common clinical presentation resulting from several different conditions, including hematological or extra-hematological diseases (mostly cancers) affecting the marrow function, as well as primary failure of hematopoiesis. Primary bone marrow failure syndromes are a heterogeneous group of diseases with specific pathogenic mechanisms, which share a profound impairment of the hematopoietic stem cell pool resulting in global or selective marrow aplasia. Constitutional marrow failure syndromes are conditions caused by intrinsic defects of HSCs; they are due to inherited germline mutations accounting for specific phenotypes, and often involve also organs and systems other than hematopoiesis. By contrast, in acquired marrow failure syndromes hematopoietic stem cells are thought to be intrinsically normal, but subjected to an extrinsic damage affecting their hematopoietic function. Direct toxicity by chemicals or radiation, as well as association with viruses and other infectious agents, can be sometimes demonstrated. In idiopathic Aplastic Anemia (AA) immunological mechanisms play a pivotal role in damaging the hematopoietic compartment, resulting in a depletion of the hematopoietic stem cell pool. Clinical and experimental evidences support the presence of a T cell-mediated immune attack, as confirmed by clonally expanded lymphocytes, even if the target antigens are still undefined. However, this simple model has to be integrated with recent data showing that, even in presence of an extrinsic damage, preexisting mutations or polymorphisms of genes may constitute a genetic propensity to develop marrow failure. Other recent data suggest that similar antigen-driven immune mechanisms may be involved in marrow failure associated with lymphoproliferative or autoimmune disorders characterized by clonal expansion of T lymphocytes, such as Large Granular Lymphocyte leukemia. In this wide spectrum, a unique and intriguing condition is Paroxysmal Nocturnal Hemoglobinuria (PNH); even in presence of a somatic mutation of the PIG-A gene carried by one or more HSCs and their progeny, the typical marrow failure in PNH is likely due to pathogenic mechanisms similar to those involved in AA, and not to the intrinsic abnormality conferred to the clonal population by the PIG-A mutation. The study of hematopoietic stem cell function in marrow failure syndromes provides hints for specific molecular pathways disturbed in many diseases of hematopoietic and non-hematopoietic stem cells. Beyond the specific interest of investigators involved in the field of these rare diseases, marrow failure syndromes represent a model that provides intriguing insight into quantity and function of normal hematopoietic stem cells, improving our knowledge on stem cell biology.


[Back to top]
Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Marc Bierings, James B. Nachman and C. Michel Zwaan

[Full Text Article]

The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in children has changed over the past decade. In pediatric acute lymphoblastic leukemia (ALL), the overall cure-rate is high with conventional chemotherapy. However, selected patients with a high-risk of relapse are often treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first remission (CR1). Patients with a bone-marrow relapse who attain a second remission frequently receive HSCT. High minimal residual disease (MRD) levels directly prior to HSCT determines the relapse risk. Therefore, MRD positive patients are eligible for more experimental approaches such as intensified or experimental chemotherapy pre-HSCT, as well as immune modulation post-HSCT. In pediatric acute myeloid leukemia (AML) the role of allo-HSCT in CR1 is declining, due to better outcome with modern multi-agent chemotherapy. In relapsed AML patients, allo-HSCT still seems indispensable. Targeted therapy may change the role of HSCT, in particular in chronic myeloid leukemia, where the role of allografting is changing in the imatinib era. In MDS, patients are usually transplanted immediately without prior cytoreduction. New developments in HSCT, such as the role of alternative conditioning regimens, and innovative stem cell sources such as peripheral blood and cord blood, will also be addressed.


[Back to top]
High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review
Giuseppe Luigi Banna, Matteo Simonelli and Armando Santoro

[Full Text Article]

High-dose chemotherapy (HDCT) plus autologous hematopoietic stem-cell transplantation (HSCT) has been explored in several solid tumors in the attempt to prevent and/or overcome tumor-cell chemo-resistance, based on in vitro evidence of a “dose-response” effect. Preliminary encouraging results from non-randomized trials, led to an increased use of this strategy in the 1990s. Since the end of the nineties, the fraudulent nature of initial reports in breast cancer, the failure of positive prospective randomized trials, HDCT-related toxicities, determined a dramatic decline of interest in this approach. Loss of accrual in ongoing randomized studies was the first consequence, causing the current unavailability of optimal information. From the review of available published data, the use of HDCT with autologous HSCT may improve tumor response rates and/or possibly progression-free survival, especially in some selected patient subgroups. However, this strategy did not demonstrate in almost all cases to produce significantly higher cure rates than standard-dose chemotherapy. Well-designed randomized studies and future strategies integrating HDCT with concomitant and/or subsequent anti-tumor therapies targeted against the residual disease might be suggested in clinically and biologically selected patients.


[Back to top]
Regenerative Medicine and Liver Injury: What Role for Bone Marrow Derived Stem Cells?
Stefania Lorenzini and Pietro Andreone

[Full Text Article]

In recent years, great interest has been aroused by the discovery of the ability of adult stem cells to contribute to regeneration processes and repair of damaged tissues. In particular, bone marrow derived stem cells (BMSCs), the most well known population of multipotent stem cells in adults, have been shown to be able to generate many different committed cellular types. In this review, we systematically organize the numerous hypotheses emerging from the most recent studies, in animal and humans, which evaluated the potentiality of BMSCs to contribute to tissue repair in different types of liver damage. Our aim is to give scientists and clinicians who are interested in regenerative medicine the rational basis for planning future studies on stem cell therapy for liver diseases.


[Back to top]
Stem Cell Migration: A Quintessential Stepping Stone to Successful Therapy
Corinna Weidt, Bernd Niggemann, Benjamin Kasenda, Theodore L. Drell, Kurt S. Zänker and Thomas Dittmar

[Full Text Article]

Migration is an innate and fundamental cellular function that enables hematopoietic stem cells (HSCs) and endothelial progenitors (EPCs) to leave the bone marrow, relocate to distant tissue, and to return to the bone marrow. An increasing number of studies demonstrate the widening scope of the therapeutic potential of both HSCs and endothelial cells. Therapeutic success however not only relies upon their ability to repair damaged tissue, but is also fundamentally dependent on the migration to these areas. Extensive in vivo and in vitro research efforts have shown that the most significant effects seen on HSC migration are initiated by the chemokine SDF-1α. In this review we will elucidate the many cellular and systemic factors of HSC and EPC cell migration and their modi operandi.


[Back to top]
Hematopoietic Stem Cell Transplantation from Alternative Donors for High-Risk Acute Leukemia: The Haploidentical Option
Franco Aversa, Antonio Tabilio, Andrea Velardi, Adelmo Terenzi, Franca Falzetti, Alessandra Carotti, Teresa Aloisi, Maria Liga, Mauro Di Ianni, Tiziana Zei, Antonella Santucci and Massimo F. Martelli

[Full Text Article]

Much progress has been made in the clinical, biological and technical aspects of the T-cell-depleted full-haplotype mismatched transplants for acute leukemia. Our experience demonstrates that infusing a megadose of extensively T-cell-depleted hematopoietic peripheral blood stem cells after an immuno-myeloablative conditioning regimen in acute leukemia patients ensures sustained engraftment with minimal graft-vs-host disease (GvHD) without the need of any post-transplant immunosuppressive treatment.

Since our first successful pilot study, our efforts have concentrated on developing new conditioning regimens, optimizing the graft processing and improving the post-transplant immunological recovery. The results we have so far achieved in more than 200 high-risk acute leukemia patients show that haploidentical transplantation is now a clinical reality. Because virtually all patients in need of a hematopoietic stem cell transplant have a full-haplotype mismatched donor, who is immediately available, a T-cell depleted mismatched transplant should be offered, not as a last resort, but as a viable option to high risk acute leukemia patients who do not have, or cannot find, a matched donor.